These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23959668)

  • 1. Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients.
    Naumnik B; Klejna K; Koc-Żórawska E; Myśliwiec M
    Adv Med Sci; 2013; 58(2):382-7. PubMed ID: 23959668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
    Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
    Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
    Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A; Data V; Carignola R; Calzolari G; Vitetta R; Ventura M; Saba L; Severino A; Angeli A
    J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
    Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
    Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
    Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
    Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
    Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
    Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease].
    Xu DR; Su C; Zou WY; Xu HR; Huang S; Li J; Luo SK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):376-80. PubMed ID: 20416172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation.
    Cao H; Wu Y; Li Q; Wu Y; Zhou Q; Røe OD; Chen Y; Wang R; Wang D
    Int J Cardiol; 2014 Jan; 170(3):298-302. PubMed ID: 24326209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concentration measurement of the OPG and sRANKL of peripheral blood among normal healthy people].
    Zhu LL; Bao NR; Zhou LW; Guo T; Zeng XF; Zhao JN
    Zhongguo Gu Shang; 2010 Feb; 23(2):87-9. PubMed ID: 20345025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.